Oruka Therapeutics, Inc.ORKAEarnings & Financial Report
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for unmet medical needs, primarily in oncology and immunology disease areas. It operates mainly in the United States, advancing its proprietary pipeline of drug candidates to address hard-to-treat patient populations across core therapeutic segments.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-2.6M
Net Profit
$-2.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.16
Oruka Therapeutics, Inc. Q3 FY2022 Financial Summary
Oruka Therapeutics, Inc. reported revenue of $0 for Q3 FY2022, with a net profit of $-2.3M (up 50.5% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-2.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2022 |
Oruka Therapeutics, Inc. Annual Revenue by Year
Oruka Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2022 | $0 |
Oruka Therapeutics, Inc. Quarterly Revenue & Net Profit History
Oruka Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2024 | $0 | — | $-22.2M | N/A |
| Q1 FY2024 | $0 | — | $-2.0M | N/A |
| Q3 FY2023 | $0 | — | $-1.4M | N/A |
| Q2 FY2023 | $0 | — | $-1.5M | N/A |
| Q1 FY2023 | $0 | — | $-1.3M | N/A |
| Q4 FY2022 | $0 | — | $-1.2M | N/A |
| Q3 FY2022 | $0 | — | $-2.3M | N/A |
| Q2 FY2022 | $0 | — | $-3.1M | N/A |
Income Statement
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $48.1M | $45.0M | $43.1M | $42.1M | $41.1M | $39.2M | $36.7M | $33.8M |
| Liabilities | $3.1M | $2.2M | $1.4M | $1.5M | $1.8M | $1.2M | $1.6M | $1.3M |
| Equity | $45.0M | $42.7M | $41.7M | $40.5M | $39.2M | $38.0M | $-7.1M | $-29.0M |
Cash Flow
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.6M | $-2.5M | $-1.5M | $-1.6M | $-694000 | $-1.7M | $-1.5M | $-2.6M |